GHRP-2

Introduction to GHRP-2

GHRP-2, also known as pralmorelin, is a synthetically produced growth hormone secretagogue that functions through ghrelin receptor activation. As the first compound of its type, it has been instrumental in advancing endocrine and metabolic research. GHRP-2 is currently utilized in controlled laboratory and diagnostic studies focused on hormone deficiency and continues to be examined for its influence on muscle maintenance, immune responsiveness, appetite signaling, and sleep patterns. Experimental evidence indicates oral and sublingual activity in non-human models.

Structural Characteristics

The molecular design of GHRP-2 consists of a short peptide sequence optimized for selective receptor engagement within growth hormone signaling systems.

Research-Observed Effects

1. Muscle Preservation

Research using animal models demonstrates that GHRP-2 promotes muscle retention by enhancing protein synthesis and reducing proteolytic signaling. In growth-compromised yaks, administration of GHRP-2 reduced muscle degradation through suppression of atrogin-1 and MuRF1 activity, offering insight into mechanisms relevant to muscle wasting research.

2. Appetite Effects

GHRP-2 has been shown to stimulate food intake in experimental settings. Appetite modulation remains a key consideration in studies of metabolic balance and disease-associated nutritional deficits.

3. Cardiac Tissue Research

Studies involving cultured cardiac cells indicate that GHRP-2 reduces apoptosis and supports mitochondrial function. Animal research has further identified specific cardiac receptors responsive to this peptide, contributing to broader understanding of cardiovascular signaling.

4. Immune System Research

By stimulating thymic activity, GHRP-2 enhances T-cell production essential for adaptive immunity. These findings are particularly relevant to investigations into immune aging and reduced immune competence.

5. Sleep Architecture

Experimental observations suggest that GHRP-2 increases time spent in deep sleep stages and modifies REM sleep patterns. Such changes are associated with improvements in recovery and overall physiological function.

6. Pain Modulation

Analgesic effects observed in animal models were determined to be independent of growth hormone release, indicating a direct role in pain pathway modulation through selective opioid receptor interaction.

GHRP-2 has shown low toxicity and favorable bioavailability in animal studies. Translation of dosing data to humans has not been established. GHRP-2 is designated strictly for research and educational use and is not approved for human administration.

Article Author

This article was researched and assembled by Dr. Logan, M.D., a physician with training from Case Western Reserve University School of Medicine and a background in molecular biology.

Scientific Researcher Acknowledgment

Jean-Alain Fehrentz, Ph.D., is a leading researcher in peptide and receptor ligand chemistry with extensive academic and industrial experience.

Referenced Citations

1. R. Hu et al., "Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation," PloS One, vol. 11, no. 2, p. e0149461, 2016.
2. D. Yamamoto et al., "GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1," Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008.
3. L. T. Phung et al., "The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine," Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.
4. B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men," J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005.
5. B. Laferrère, A. B. Hart, and C. Y. Bowers, "Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake," Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006.
6. G. Muccioli et al., "Growth hormone-releasing peptides and the cardiovascular system," Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000.
7. V. Bodart et al., "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart," Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999.
8. D. D. Taub, W. J. Murphy, and D. L. Longo, "Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways," Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010.
9. G. Gopinadh et al., "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man," Neuroendocrinology, vol. 66, no. 4, pp. 278–286, Oct. 1997.
10. P. Zeng et al., "Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice," Peptides, vol. 55, pp. 103–109, May 2014.
11. Moulin, A. , Ryan, J. , Martinez, J. and Fehrentz, J. (2007), Recent Developments in Ghrelin Receptor Ligands. ChemMedChem, 2: 1242-1259.